Recommendation to lift PBS restrictions on ICS+LABA access in children

Clinician concerns about the PBS age restrictions for ICS+LABA fixed dose combination (FDC) products in asthma have led to a proposed change in PBS listings to allow second line treatment. At its December 2019 meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended a separate Authority Required (STREAMLINED) code for ICS+LABA FDC products other than fluticasone ...